Utilization of novel therapeutics in the frontline setting across race/ethnicity
| . | . | Pre era . | Post era . | ||||
|---|---|---|---|---|---|---|---|
| NHW . | NHB . | Hispanic . | NHW . | NHB . | Hispanic . | ||
| High intensity | |||||||
| All | Adjusted %∗ | 58 | 57 | 57 | 37 | 37 | 35 |
| aPR (95% CI) | Ref | 0.97 (0.88-1.08) | 0.98 (0.89-1.07) | Ref | 1.00 (0.85-1.17) | 0.94 (0.81-1.10) | |
| ≤70 y | Adjusted %∗ | 86 | 84 | 83 | 67 | 72 | 70 |
| aPR (95% CI) | Ref | 0.97 (0.91-1.04) | 0.96 (0.90-1.02) | Ref | 1.06 (0.94-1.20) | 1.04 (0.93-1.16) | |
| Venetoclax low intensity | |||||||
| All | Adjusted %∗ | 2 | 1 | 1 | 44 | 40 | 43 |
| aPR (95% CI) | Ref | 0.50 (0.12-2.03) | 0.30 (0.04-1.14) | Ref | 0.93 (0.77-1.12) | 0.99 (0.80-1.22) | |
| >70 y | Adjusted %∗ | Small event sizes | 61 | 61 | 66 | ||
| aPR (95% CI) | Ref | 1.01 (0.83-1.23) | 1.09 (0.88-1.34) | ||||
| CPX-351 in s-AML† | |||||||
| All | Adjusted %∗ | 24 | 26 | 32 | 15 | 20 | 10 |
| aPR (95% CI) | Ref | 1.07 (0.61-1.88) | 1.32 (0.70-2.50) | Ref | 1.33 (0.87-2.04) | 0.67 (0.31-1.48) | |
| ≤70 y | Adjusted %∗ | 40 | 41 | 55 | Small event sizes | ||
| aPR (95% CI) | Ref | 1.02 (0.58-1.80) | 1.39 (0.75-2.59) | ||||
| Midostaurin in FLT3-mutated AML† | |||||||
| All | Adjusted %∗ | 45 | 38 | 22 | 42 | 45 | 37 |
| aPR (95% CI) | Ref | 0.85 (0.36-2.00) | 0.52 (0.22-1.24) | Ref | 1.06 (0.69-1.61) | 0.87 (0.54-1.38) | |
| ≤70 y | Adjusted %∗ | Small event sizes | 56 | 62 | 54 | ||
| aPR (95% CI) | Ref | 1.10 (0.75-1.60) | 0.97 (0.62-1.51) | ||||
| . | . | Pre era . | Post era . | ||||
|---|---|---|---|---|---|---|---|
| NHW . | NHB . | Hispanic . | NHW . | NHB . | Hispanic . | ||
| High intensity | |||||||
| All | Adjusted %∗ | 58 | 57 | 57 | 37 | 37 | 35 |
| aPR (95% CI) | Ref | 0.97 (0.88-1.08) | 0.98 (0.89-1.07) | Ref | 1.00 (0.85-1.17) | 0.94 (0.81-1.10) | |
| ≤70 y | Adjusted %∗ | 86 | 84 | 83 | 67 | 72 | 70 |
| aPR (95% CI) | Ref | 0.97 (0.91-1.04) | 0.96 (0.90-1.02) | Ref | 1.06 (0.94-1.20) | 1.04 (0.93-1.16) | |
| Venetoclax low intensity | |||||||
| All | Adjusted %∗ | 2 | 1 | 1 | 44 | 40 | 43 |
| aPR (95% CI) | Ref | 0.50 (0.12-2.03) | 0.30 (0.04-1.14) | Ref | 0.93 (0.77-1.12) | 0.99 (0.80-1.22) | |
| >70 y | Adjusted %∗ | Small event sizes | 61 | 61 | 66 | ||
| aPR (95% CI) | Ref | 1.01 (0.83-1.23) | 1.09 (0.88-1.34) | ||||
| CPX-351 in s-AML† | |||||||
| All | Adjusted %∗ | 24 | 26 | 32 | 15 | 20 | 10 |
| aPR (95% CI) | Ref | 1.07 (0.61-1.88) | 1.32 (0.70-2.50) | Ref | 1.33 (0.87-2.04) | 0.67 (0.31-1.48) | |
| ≤70 y | Adjusted %∗ | 40 | 41 | 55 | Small event sizes | ||
| aPR (95% CI) | Ref | 1.02 (0.58-1.80) | 1.39 (0.75-2.59) | ||||
| Midostaurin in FLT3-mutated AML† | |||||||
| All | Adjusted %∗ | 45 | 38 | 22 | 42 | 45 | 37 |
| aPR (95% CI) | Ref | 0.85 (0.36-2.00) | 0.52 (0.22-1.24) | Ref | 1.06 (0.69-1.61) | 0.87 (0.54-1.38) | |
| ≤70 y | Adjusted %∗ | Small event sizes | 56 | 62 | 54 | ||
| aPR (95% CI) | Ref | 1.10 (0.75-1.60) | 0.97 (0.62-1.51) | ||||